Latest Insider Transactions at Exelixis, Inc. (EXEL)
This section provides a real-time view of insider transactions for Exelixis, Inc. (EXEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXELIXIS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXELIXIS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 27
2021
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+17.14%
|
-
|
|
May 27
2021
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,424
+1.24%
|
-
|
|
May 27
2021
|
Vincent T Marchesi Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+10.03%
|
-
|
|
May 27
2021
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,299
+3.34%
|
-
|
|
May 18
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
14,593
-4.94%
|
$350,232
$24.73 P/Share
|
|
May 17
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-2.89%
|
$450,000
$25.39 P/Share
|
|
May 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
3,026
-1.01%
|
$75,650
$25.56 P/Share
|
|
May 14
2021
|
George Poste Director |
SELL
Open market or private sale
|
Direct |
40,802
-20.61%
|
$979,248
$24.97 P/Share
|
|
May 14
2021
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
40,000
-37.7%
|
$1,000,000
$25.04 P/Share
|
|
May 14
2021
|
Vincent T Marchesi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+27.38%
|
$240,000
$6.3 P/Share
|
|
May 14
2021
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
19,722
+1.86%
|
-
|
|
May 14
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
19,722
-3.86%
|
-
|
|
May 13
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
100,000
-14.0%
|
$2,500,000
$25.38 P/Share
|
|
May 13
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.28%
|
$100,000
$1.9 P/Share
|
|
May 12
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,278
-5.59%
|
$756,950
$25.16 P/Share
|
|
May 12
2021
|
Michael Morrissey President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.45%
|
$200,000
$4.2 P/Share
|
|
May 11
2021
|
Maria C Freire Director |
SELL
Open market or private sale
|
Direct |
8,275
-20.63%
|
$206,875
$25.01 P/Share
|
|
May 11
2021
|
Stelios Papadopoulos Director |
SELL
Open market or private sale
|
Direct |
20,770
-0.55%
|
$498,480
$24.99 P/Share
|
|
May 11
2021
|
Stelios Papadopoulos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
120,000
+3.08%
|
$480,000
$4.27 P/Share
|
|
May 10
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
40,616
-3.83%
|
-
|
|
Apr 26
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-2.79%
|
$450,000
$25.03 P/Share
|
|
Apr 26
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
7,665
-2.51%
|
$191,625
$25.03 P/Share
|
|
Apr 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-7.54%
|
$1,250,000
$25.0 P/Share
|
|
Apr 26
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.01%
|
$50,000
$1.7 P/Share
|
|
Apr 01
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-7.54%
|
$1,150,000
$23.0 P/Share
|
|
Apr 01
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.01%
|
$50,000
$1.7 P/Share
|
|
Apr 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
60,000
-13.35%
|
$1,320,000
$22.96 P/Share
|
|
Apr 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+11.78%
|
$60,000
$1.7 P/Share
|
|
Mar 29
2021
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
6,220
-2.62%
|
$136,840
$22.64 P/Share
|
|
Mar 29
2021
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+14.4%
|
$120,000
$3.38 P/Share
|
|
Mar 15
2021
|
Alan M Garber Director |
SELL
Open market or private sale
|
Direct |
40,000
-75.88%
|
$920,000
$23.6 P/Share
|
|
Mar 15
2021
|
Alan M Garber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+43.14%
|
$120,000
$3.38 P/Share
|
|
Mar 04
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
49,395
+11.26%
|
-
|
|
Mar 04
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
59,570
+16.34%
|
-
|
|
Mar 04
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
64,150
+15.25%
|
-
|
|
Mar 04
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
57,135
+8.12%
|
-
|
|
Mar 04
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
72,885
+10.62%
|
-
|
|
Mar 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-16.05%
|
$1,430,000
$22.11 P/Share
|
|
Mar 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+13.83%
|
$65,000
$1.7 P/Share
|
|
Feb 24
2021
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
67,374
+5.98%
|
-
|
|
Feb 24
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
67,374
-12.05%
|
-
|
|
Feb 24
2021
|
Charles Cohen Director |
SELL
Open market or private sale
|
Direct |
40,000
-18.07%
|
$880,000
$22.69 P/Share
|
|
Feb 24
2021
|
Charles Cohen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.3%
|
$120,000
$3.38 P/Share
|
|
Feb 23
2021
|
Lance Willsey Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.31%
|
$880,000
$22.13 P/Share
|
|
Feb 23
2021
|
Lance Willsey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.93%
|
$120,000
$3.38 P/Share
|
|
Feb 22
2021
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
24,097
-26.71%
|
$530,134
$22.29 P/Share
|
|
Feb 22
2021
|
George Poste Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.81%
|
$120,000
$3.38 P/Share
|
|
Feb 18
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-8.47%
|
$1,100,000
$22.35 P/Share
|
|
Feb 18
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.81%
|
$50,000
$1.7 P/Share
|
|
Feb 17
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-8.47%
|
$1,100,000
$22.5 P/Share
|